ArticleBMC gastroenterology2026
MiR-551b-5p deficiency associates with malignant phenotypes in gastric cancer: potential mediation by TRAF6.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The inflammatory tumor microenvironment (i-TME) significantly impacts the prognosis of gastric cancer (GC). Cytokines such as IL-6 may contribute to adverse phenotypes in GC; however, their regulatory mechanisms remain unclear. The role of miR-551b-5p in other cancers suggests it can target inflammation-related genes to regulate the i-TME and influence tumor prognosis. The present study aimed to investigate whether miR-551b-5p regulates the i-TME in GC and affects GC prognosis. Reverse transcription-quantitative PCR (RT-qPCR), western blotting, dual-luciferase reporter assays, cell scratch wound healing assays, Annexin V-FITC/PI double staining and in vitro angiogenesis assays were employed to investigate the differential expression of miR-551b-5p and TNF receptor-associated factor 6 (TRAF6) between GC tumors and normal tissues, and to explore the relationship between their expression levels and inflammatory cytokines. Prognostic analysis, immune infiltration assessment, oncogenic pathway analysis and single-cell Uniform Manifold Approximation and Projection analysis were used to validate the relationship between IL-6 and malignant phenotypes in GC. Experimental results demonstrated a significant deficiency of miR-551b-5p expression in GC. miR-551b-5p was found to target and inhibit TRAF6. Overexpression of TRAF6 was associated with increased IL-6 expression within the inflammatory microenvironment, and correlated with enhanced tumor cell proliferation, invasion, and poorer prognosis in gastric cancer. Deficiency of miR-551b-5p may lead to TRAF6 overactivation, which is associated with elevated IL-6 levels and malignant phenotypes in gastric cancer. miR-551b-5p and TRAF6 may serve as crucial molecular targets for GC therapy and prognostic prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.